Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Optimization of the Acquisition Sequence to Improve the Quality and Comfort of Magnetic Resonance Imaging Exam

NCT04645628 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2020-12-04
Last updated
2026-03-04

Condition(s) studied

Healthy SubjectsPatient Performing an MRI Examination

Investigational drug(s) / intervention(s)

MRI examination

MRI examination: All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences

Study summary

The purpose of this study is to evaluate the optimization of MRI acquisition sequences.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for all subjects : * to be over 18 year-old, * to be able to understand the instructions given, * to be enrolled in a social security plan, * to have underwent a pre-inclusion medical examination, * to give a written consent. Inclusion Criteria especially for Patients : * to perform a MRI examination of the head, neck, spine, thorax, abdomen, pelvis, retroperitoneum, lower limbs, upper limbs or whole body during clinical follow-up care. Exclusion Criteria for all subjects : * any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ), * subject under a measure of legal protection. Exclusion Criteria especially for Healthy Subjects : * to have a pathology in the anatomical area to be imaged * to be employed by the CHRU of Nancy or having the slightest link of subordination with the CHRU of Nancy. Exclusion Criteria especially for Patients : * to have a limited MRI examination time due to a sensitive clinical situation (sedation, unstable hemodynamic state, postoperative).

Primary outcome measure(s)

  • Image quality based on standard imaging quality criteria. — 6 months after the last inclusion
    The image quality will be appreciated visually at least by a radiologist or a researcher.

Trial sites (1)

FacilityCityRegionStatus
CHRU de Nancy Nancy France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04645628 on ClinicalTrials.gov ↗ ← All trials in France